Revolutionizing HIV/aids treatment: advances in CRISPR/Cas9
DOI:
https://doi.org/10.1590/s2175-97902026e24485Keywords:
CRISPR/Cas9, Antiretroviral therapy (ART), HIV research, HIV treatmentsAbstract
Human immunodeficiency virus (HIV) is a significant health issue globally and affects millions of people worldwide each year. The infection is treated using antiretroviral therapy (ART) and considered as standard treatment for HIV. The therapy consists of a combination of medicines that slow down or suppress the replication of the virus. Although ART therapy has been successful in managing HIV infection it is not the cure and requires life-long adherence to remain effective. Hence scientists and health workers around the globe are looking for more effective therapy that eliminates the virus from the patient body. Genomic medicine is one of the most significant therapies among these novel treatment procedures. The current advances in genomic medicine and genetic engineering, especially the discovery of CRISPR/Cas9 offer new hope to fight against HIV. In this study, we investigate the current advances in CRIPSR/Cas9 base therapy against HIV. Further, the basics of CRISPR/Cas9 technology, its application in HIV research, challenges, and future perspectives were also investigated.
Downloads
References
Abadi T, Teklu T, Wondmagegn T, Alem M, Desalegn G. CD4+ T cell count and HIV-1 viral load dynamics positively impacted by H. pylori infection in HIV-positive patients regardless of ART status in a high-burden setting. Eur J Pharm Med Res. 2024;29(1):178.
Adler BA, Trinidad MI, Bellieny-Rabelo D, Zhang E, Karp HM, Skopintsev P, et al. CasPEDIA Database: a functional classification system for class 2 CRISPR-Cas enzymes. Nucleic Acids Res. 2024;52(D1):D590-6.
Addissouky TA, El Sayed IE, Ali MM, Alubiady MH, Wang Y. Bending the Curve Through Innovations to Overcome Persistent Obstacles in HIV Prevention and Treatment. J AIDS HIV Res. 2024;6(1):44-53.
Adeniji FO, Ogubuike C. HIV Risk Perception and Assessment among Youths in Rivers State, Nigeria: A Comparative Cross-sectional Study. Int STD Res Rev. 2024;13(1):32-42.
Allemailem KS, Almatroudi A, Rahmani AH, Alrumaihi F, Alradhi AE, Alsubaiyel AM, et al. Recent Updates of the CRISPR/Cas9 Genome Editing System: Novel Approaches to Regulate Its Spatiotemporal Control by Genetic and Physicochemical Strategies. Int J Nanomed. 2024;31:5335-63.
Alckmin-Carvalho F, Pereira H, Nichiata L. "It'sa Lot of Closets to Come Out of in This Life": Experiences of Brazilian Gay Men Living with Human Immunodeficiency Virus at the Time of Diagnosis and Its Biopsychosocial Impacts. Eur J Investig Health Psychol. 2024;14(4):1068-85.
Bune GT. Low-level physical activity predictors among adults living with HIV in Ethiopia's southern region, focusing on work, transportation, and recreation domains: an unmatched case-control study. BMC Sports Sci Med. 2024;16(1):1-4.
Debie Anggraini DA. Immunopathogenesis of HIV Infection: The Complex Role of the Immune System in Disease Development and Control (doc). Nusantara Hasana Journal. 2024;3(7).
Dudek AM, Feist WN, Sasu EJ, Luna SE, Ben-Efraim K, Bak RO, et al. A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5-and CXCR4-tropic HIV-1 infection. Cell Stem Cell. 2024;31(4):499-518.
Ezemba CC, Osuala OJ, Etikudike VO, Ogunleye SC, Ezemba PI, Iyiola O, et al. Molecular viral infections and antiviral therapeutics. InBiochemical Mol Pharm Drug Discovery. 2024:515-540.
Gurrola TE, Effah SN, Sariyer IK, Dampier W, Nonnemacher MR, Wigdahl B. Delivering CRISPR to the HIV-1 reservoirs. Front Microbiol. 2024;15:1393974.
Haraka F, Moore A, Odinga G, Bailey R, Songoro J, Haule D, et al. Accuracy, use and acceptability of the VISITECT CD4 semi-quantitative test to advance HIV disease screening in routine programmatic settings in Tanzania. Clin Epidemiol Glob Health. 2024;27:101616.
Harfmann M, Schröder T, Głów D, Jung M, Uhde A, Kröger N, et al. CD45-Directed CAR-T Cells with CD45 Knockout Efficiently Kill Myeloid Leukemia and Lymphoma Cells In Vitro Even after Extended Culture. Cancers. 2024;16(2):334.
Haugeberg KA. Filling the Unforgiving Minute with Sixty Seconds' Worth of Effort: Barbara Fassbinder, Nursing, and AIDS in the US, 1986–91. Middle West Rev. 2024;10(2):205-25.
Haag SM, Xie S, Eidenschenk C, Fortin JP, Callow M, Costa M, et al. Systematic perturbation screens decode regulators of inflammatory macrophage states and identify a role for TNF mRNA m6A modification. bioRxiv. 2024;2024-04.
Huang X, Wang G, Huang J, Liang W, Guan H, Liu H, et al. Bioequivalence and Pharmacokinetics Study of Two Zidovudine/Lamivudine Tablets in Chinese Healthy Volunteers. Clin Pharmacol Drug Dev. 2024;13(1):14-20.
Hussein M, Molina MA, Berkhout B, Herrera-Carrillo E. A CRISPR-Cas Cure for HIV/AIDS. Int J Mol Sci. 2023; 24(2):1563.
Iqbal T, Altaf S, Ahmad A. Overview of Acquired Immunodeficiency Syndrome (AIDS): A Chronic Condition Caused by Human Immunodeficiency Virus (HIV). 2024.
Izquierdo-Pujol J, Puertas MC, Martinez-Picado J, Morón-López S. Targeting Viral. Transcription for HIV Cure Strategies. Microorganisms. 2024;12(4):752.
Jain MS, Srikruthi KS, Goudanavar P, Naveen NR. Navigating the Frontier: Comprehensive insights into CRISPR technology advancements, delivery strategies, and ethical considerations in cancer research. Oral Oncol Rep. 2024:100224.
Jiang F, Doudna JA. CRISPR–Cas9 structures and mechanisms. Annu Rev Biophys. 2017;46(1):505-29.
Khamaikawin W, Saisawang C, Tassaneetrithep B, Bhukhai K, Phanthong P, Borwornpinyo S, et al. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1. Sci Rep. 2024;14(1):10852.
Khadempar S, Familghadakchi S, Motlagh RA, Farahani N, Dashtiahangar M, Rezaei H, Gheibi Hayat SM. CRISPR–Cas9 in genome editing: Its function and medical applications. J Cell Physiol. 2019;234(5):5751-61.
Khoshandam M, Soltaninejad H, Mousazadeh M, Hamidieh AA, Hosseinkhani S. Clinical applications of the CRISPR/Cas9 genome-editing system: delivery options and challenges in precision medicine. Genes Dis. 2024;11(1):268-82.
Kitawi R, Ledger S, Kelleher AD, Ahlenstiel CL. Advances in HIV Gene Therapy. Int J Mol Sci. 2024;25(5):2771.
Klinnert S, Schenkel CD, Freitag PC, Günthard HF, Plückthun A, Metzner KJ. Targeted shock-and-kill HIV-1 gene therapy approach combining CRISPR activation, suicide gene tBid, and retargeted adenovirus delivery. Gene Ther. 2024;31(3):74-84.
Kropf M. The ethically significant difference between dual use and slippery slope arguments in relation to CRISPR-Cas9: philosophical considerations and ethical challenges. Res Ethics. 2024:17470161241240587.
Kyobe S, Kisitu G, Mwesigwa S, Farirai J, Katagirya E, Retshabile G, et al. Long-term non-progression and risk factors for disease progression among children living with HIV in Botswana and Uganda: A retrospective cohort study. Int J Infect Dis. 2024;139:132-40.
Khatun S, Amin SA, Choudhury D, Chowdhury B, Jha T, Gayen S. Advances in structure-activity relationships of HDAC inhibitors as HIV latency-reversing agents. Expert Opin Drug Discov. 2024;19(3):353-68.
Li K, Zhang Q. Eliminating the HIV tissue reservoir: current strategies and challenges. Infect Dis. 2024;56(3):165-82.
Lucas S. The changing face of HIV pathology: a personal perspective. Diagn Histopathol. 2024.
Mami D, Cuthrell KM, Manteghian M. Burden of HIV on Society: Current Management Options and Future Prospective. Int STD Res Rev. 2024;13(1):43-62.
Manchanda P, Kaur J, Kaur H, Kaur G. Development of virus-resistant horticultural crops through CRISPR/Cas mediated genome editing: applications and future prospects. The Nucleus. 2024;25:1-7.
Markley JD. Pre-Exposure Prophylaxis for HIV: Bioethical, Clinical, and Epidemiological Considerations. Linacre Q. 2024:00243639241239068.
McLaurin KA, Li H, Khalili K, Mactutus CF, Booze RM. HIV-1 mRNA knockdown with CRISPR/CAS9 enhances neurocognitive function. J NeuroVirol. 2024;14:1-5.
Mojahedi A. Evaluating the use of antiviral drugs in HIV patients with cardiovascular diseases and how to reduce the incidence of cardiac events in these patients. Am J Cardiovasc Dis. 2024;14(2):70.
Matsuda K, Maeda K. HIV Reservoirs and Treatment Strategies toward Curing HIV Infection. Int J Mol Sci. 2024;25(5):2621.
Nagtilak V, Mulani S, Kumbhar R, Kumbhar P, Sable A, Chavan A, et al. Prevention, Treatment and Diagnosis of HIV and AIDS: A Review. Res J Sci Technol. 2024;16(1):68-74.
Nyman F. Reshaping the narrative: Tracing the historical trajectory of HIV/AIDS, gay men, and public health in Sweden. PLOS One. 2024;19(2):e0298630.
ObeaguEI OG. A Roadmap for Reducing HIV Transmission from Mother to Child: Strategies, Challenges, and Future Directions. Elite J HIV. 2024;2(4):91-109.
Olsson O. Immune mediators in people with HIV and tuberculosis. 2024.
Parker R. Epidemics of signification and global health policy: from the end of AIDS to the end of scale-up of the global AIDS response. Glob Public Health. 2024;19(1):2327523.
Payra S, Manjhi PK, Singh S, Kumar R, Singh SK, Kumar A, et al. HIV cure: Are we going to make history? HIV Med. 2024;25(3):322-31.
Poswa NL, Sibiya DM. Direct Characterization and the Depiction of HIV/AIDS Theme in the Zulu Novel, Ngidedele Ngife. Int J Soc Sci. 2024;7(6):1-3.
Rahayu EP, Rizki LK, Novianti H, Anggraini FD, Gusmao C, Fernandes I, et al. Comparative Study of Indonesia and Timor Leste on the Psychological Conditions, Social Support, and Immunity of People Living with HIV/AIDS (PLWHA). SEEJPH.2024;29:317–321. Available at: https://www.seejph.com/index.php/seejph/article/view/708.
Rautenbach SP, Whittles LK, Meyer-Rath G, Jamieson L, Chidarikire T, Johnson LF, et al. Future HIV epidemic trajectories in South Africa and the projected long-term consequences of reductions in general population HIV testing: a mathematical modeling study. The Lancet Public Health. 2024;9(4):e218-30.
Saifullah M, Laghzaoui O, Ozyahyalar H, Irfan A. The CRISPR-Cas9-induced CCR5 Δ32 mutation as a potent gene therapy methodology for resistance to HIV-1 variants: a review. Eur Rev Med Pharmacol Sci. 2024;28(6).
Sever B, Otsuka M, Fujita M, Ciftci H. A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication. Int J Mol Sci. 2024 Mar 25;25(7):3659.
Tassaneetrithep B, Phuphuakrat A, Pasomsub E, Bhukhai K, Wongkummool W, Priengprom T, et al. HIV-1 proviral DNA in purified peripheral blood CD34+ stem and progenitor cells in individuals with long-term HAART; paving the way to HIV gene therapy. Heliyon. 2024.
Vasconcelos Komninakis S, Domingues W, Saeed Sanabani S, Angelo Folgosi V, Neves Barbosa I, Casseb J. CRISPR/CAS as a powerful tool for human immunodeficiency virus cure: a review. AIDS Res Hum Retrovir. 2024;40(6):363-75.
Wang X, Li Y, Huang X. CRISPR/Cas-based diagnosis and treatment of infectious diseases. Mol Med Microbiology: Academic Press. 2024;2039-2057.
Widiyawati W, Ratnasari D, Mulyani E, Kholifah AN, Indarto T. The Evaluation of the Achievements of the Universal Health Coverage Program in Health Facilities in Gresik District. Jurnal Nersdan Kebidanan. J Nurse Midwifery. 2024;11(1):130-8.
WHO. Why the HIV epidemic is not over [Internet]. 2024. Available at: https://www.who.int/news-room/spotlight/why-the-hiv-epidemic-is-not-over.
Wong XK, Ng CS, Yeong KY. Shaping the future of antiviral treatment: spotlight on nucleobase-containing drugs and their revolutionary impact. Bioorg Chem. 2024;27:107150.
Zahedipour F, Zahedipour F, Zamani P, Jaafari MR, Sahebkar A. Harnessing CRISPR technology for viral therapeutics and vaccines: from preclinical studies to clinical applications. Virus Res. 2024;341:199314.
Zhang L, Wang H, Zeng J, Cao X, Gao Z, Liu Z, et al. Cas1 mediates the interference stage in a phage-encoded CRISPR–Cas system. Nat Chem Biol. 2024;8:1-1.
Downloads
Published
Data Availability Statement
All data is available within the article.
Issue
Section
License
Copyright (c) 2026 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
